CD40 and neoplasm: Concerns include cytokine release syndromes, autoimmune reactions [4], thromboembolic syndromes, hyperimmune stimulation leading to activation-induced cell apoptosis or tolerance [5,6] and tumour angiogenesis, possibly as a result of the CD40-dependent activation of tumour endothelial cells [7].